Evaluating the Safety of Immune Checkpoint Inhibitors and Combination Therapies in the Management of Brain Metastases: A Comprehensive Review
Vivek Podder, Tulika Ranjan, Kim Margolin, Arun Maharaj, Manmeet Singh Ahluwalia, Mirko HH Schmidt · 2024
Read Evaluating the Safety of Immune Checkpoint Inhibitors and Combination Therapies in the Management of Brain Metastases: A Comprehensive Review by Vivek Podder, Tulika Ranjan, Kim Margolin, Arun Maharaj, Manmeet Singh Ahluwalia, Mirko HH Schmidt (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11640090.txt.
Description
Vivek Podder and co-authors present a 2024 review of immune therapy safety in brain metastases. Cancer spread to the brain is common in lung cancer, breast cancer, and melanoma. Checkpoint inhibitor drugs have become a core option there. They can be used alone or with chemotherapy and focused radiation. Their risk is immune side effects that can strike many organs. Brain patients face those risks on top of fragile neurology.
The review maps side effect mechanisms organ by organ. It grades safety across solo and combined treatment plans. Survival and control gains from the drugs are real, as the authors report. Neurologic side effects draw special care in the analysis. Oncologists get a balanced ledger for a hard trade-off. Brain spread once barred patients from such trials, so a dedicated safety record serves a group long left out.
Catalog record
| CREATOR | Vivek Podder, Tulika Ranjan, Kim Margolin, Arun Maharaj, Manmeet Singh Ahluwalia, Mirko HH Schmidt |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |